Navigation Links
Hepatitis C Phase 2A Trial Positive Results
Date:10/10/2011

SYDNEY, Oct. 10, 2011 /PRNewswire-Asia/ --

  • Phase 2a trial validates Biotron's novel drug
  • First-in-class new, oral drug
  • Good results on tolerability and efficacy
  • Full data to be presented to scientific conference in December

  • Australian drug development company Biotron Limited (ASX:BIT) has released headline results from its landmark Phase 2a trial of its lead drug candidate, BIT225 in Hepatitis C virus (HCV) infected patients.

    Preliminary analysis of trial data confirms that BIT225, an orally administered, small molecule drug, has good antiviral activity against HCV. Patients receiving BIT225 in combination with interferon and ribavirin (the current standard of care for treating HCV) had greater reductions in HCV levels than patients receiving standard of care treatment alone.

    Patients receiving the 400 mg dose of BIT225 showed the greatest levels of virus reduction, with an improvement of ~1 log (a measure of the amount of reduction of the virus in the blood of patients) over standard of care treatment at the completion of the dosing phase with BIT225. This is a significant improvement over and above the standard of care treatment in this patient group.

    Twenty four patients who had passed a stringent screening process were randomly assigned to receive either 400 mg or 200 mg BIT225, or placebo (ratio of 1:1:1), for the first 28 days of their standard treatment with interferon and ribavirin. The trial was undertaken at the Siriraj Hospital, Bangkok, Thailand. All patients were infected with genotype 1 HCV, which is the most common type of HCV and the most resistant to current treatment.

    Since the completion of the clinical phase of dosing with BIT225 in August, samples have been analysed and the resultant data has been subject to preliminary review by the independent Data Safety Monitoring Committee.

    The Company's Managing Director, Dr Michelle Miller, commented: "This highly encouraging result is the culmination of 10 years of research and development of Biotron's antiviral program. The trial has shown that BIT225 has good activity against HCV, and validates Biotron's approach to treatment of this virus."

    BIT225's antiviral activity in this human trial supports the previously reported highly synergistic activity with interferon and ribavirin that was seen in cell culture models of HCV infection.

    Robert Murphy, Professor of Medicine at Northwestern University Feinberg School of Medicine in Chicago, commented: "The results from this study provide good evidence that this novel approach to treating HCV infection has significant antiviral activity compared to the standard of care interferon plus ribavirin. Tolerability was reasonable with only one person dropping out of the study because of intolerability."

    BIT225 is the first in a new class of direct-acting antiviral drugs for HCV. It specifically targets the p7 protein, a viral protein essential to virus production and replication.

    The results of this trial will guide the future development path for this new class of direct-acting anti-HCV drug. BIT225 has the potential to be used with either interferon based therapies or with other direct-acting antiviral drugs in interferon free regimens. The drug is also in development for treatment of HIV, with a Phase 1b/2a trial currently underway. It has the potential to be used in the HCV/HIV co-infected population, which makes up to 30% of all HIV-positive cases.

    Dr Miller said that detailed analyses of the data from the trial are ongoing, and it is anticipated that full data will be available when it is presented at an international scientific conference later in 2011.

    About BiotronBiotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including influenza, Dengue and Hepatitis B.

    About BIT225 and HCVBIT225 is an investigational, orally-administered, novel antiviral compounds in development by Biotron for treatment of HCV. BIT225 represents a first-in-class drug, targeting the p7 protein of HCV. It is estimated that in the USA alone, some 4 million people have been infected with Hepatitis C with 2.7 million suffering from chronic infection. Worldwide, 170 million people are infected. HCV causes inflammation of the liver, which may lead to fibrosis and cirrhosis, liver cancer and, ultimately, liver failure. Existing drugs for HCV have limited effectiveness and toxicity issues, leaving a significant need for new therapies. The worldwide market is currently almost US$3.3 billion, but is estimated that this market will expand to over US$10.0 billion as safe, effective therapies enter the market.EnquiriesDr Michelle Miller

    Rudi MichelsonManaging Director

    Monsoon CommunicationsBiotron Limited+61-3-9620-3333+61-2-9805-0488mmiller@biotron.com.au
    '/>"/>

    SOURCE Biotron
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C
    2. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
    3. Lead Trial Attorney in Clark County Hepatitis C Trial, Robert Eglet, Asks Jury to Award $10 Million Compensatory Damages for Anne Arnold, $2.5 Million for James Arnold
    4. Updated Hepatitis C Practice Guidelines Now Available from AASLD
    5. PSI-938 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
    6. Mainor Eglet Attorney, Robert Eglet, Calls Teva Pharmaceuticals Vice President Craig Lea to the Stand in Hepatitis C Trial
    7. Second Trial in the Largest Hepatitis C Outbreak in U.S. Begins - Mainor Eglet Law Firm Files for Plaintiffs
    8. Hepatitis B Vaccine - Comprehensive Patent Search
    9. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
    10. FDA approves Incivek for hepatitis C
    11. FDA Approves Victrelis for Hepatitis C
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/5/2016)... Feb. 5, 2016  Aralez Pharmaceuticals Inc. ("Aralez") today ... Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval ... of Tribute. The combined company will operate under Aralez ... operations in Canada , ... . Under the terms of the Agreement and ...
    (Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
    (Date:2/5/2016)... MELVILLE, N.Y. , Feb. 5, 2016  Henry ... of health care products and services to office-based dental, ... has entered into an agreement to acquire a majority ... dental supplies and equipment in Brazil ... Headquartered in Blumenau, Brazil, Dental Cremer is the dental ...
    Breaking Medicine Technology:
    (Date:2/5/2016)... ... 05, 2016 , ... Francisco Canales, MD and Heather Furnas, ... Valley office. The technique utilizes the body’s own healing abilities to quickly rejuvenate ... are part of only a select few cosmetic surgeons bringing this procedure to ...
    (Date:2/5/2016)... Miami, Florida (PRWEB) , ... February 05, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – is poised to once again host, Swirl, A Wine Tasting Event ...
    (Date:2/5/2016)... , ... February 05, 2016 , ... Regular gym users ... themselves having to wait longer to access the treadmills. It’s a predictable trend. After ... to lose weight and get in shape by joining gyms, starting new walking or ...
    (Date:2/5/2016)... , ... February 05, 2016 , ... At its annual ... Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds former ... the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat has ...
    (Date:2/5/2016)... , ... February 05, 2016 , ... Colorize ... on one drop zone to the next using Colorize's dynamic moving camera. Colorize is ... This package includes a 3D slideshow environment with 1 to 5 focus points per ...
    Breaking Medicine News(10 mins):